论文部分内容阅读
目的:探讨输尿管软镜联合倒置排石床治疗肾下盏结石的疗效。方法:收治72例单侧肾下盏结石患者,随机分为实验组(输尿管软镜联合倒置排石床治疗组)和对照组(输尿管软镜治疗组)。实验组患者接受输尿管软镜碎石术1个月后拔除输尿管支架管,接受排石床治疗;对照组患者接受输尿管软镜碎石术1个月后拔除输尿管支架管,并嘱患者每日饮水2 000ml。所有患者均在拔除输尿管支架管1个月后行腹部平片复查,检查是否有结石残留。结果:所有患者顺利完成治疗。实验组与对照组患者相比,在年龄、性别、BMI、结石大小及肾内相关解剖学参数等一般情况上均差异无统计学意义。实验组患者共39例,在接受输尿管软镜联合倒置排石床治疗后,38例患者结石完全清除,结石清除率达到97.4%。对照组33例患者中,27例患者结石清除,结石清除率为81.8%,与实验组相比差异有统计学意义。结论:输尿管软镜联合倒置排石床治疗肾下盏结石具有良好的效果和安全性,此方案值得在临床上继续尝试,并加以推广。
Objective: To investigate the curative effect of ureteroscopic combined with inverted row of stone in the treatment of lower calyx stones. Methods: Totally 72 patients with unilateral lower calyceal calculus were randomly divided into experimental group (ureteroscopy combined with inverted row stone bed treatment group) and control group (ureteroscopic treatment group). Patients in the experimental group were treated with ureteroscopic lithotripsy one month after removal of the ureteral stent and were treated with row of stone beds. Patients in the control group underwent ureteroscopic lithotripsy after one month of removal of the ureteral stent and instructed the patients to drink water daily 2 000 ml. All patients underwent ureteral stent removal 1 month after the line plain film review to check whether there is residual stones. Results: All patients completed the treatment successfully. Compared with the control group, there was no significant difference in the general conditions such as age, sex, BMI, stone size and renal related anatomical parameters between the experimental group and the control group. A total of 39 patients in the experimental group were treated with ureteroscopy combined with inverted row stone bed, 38 patients with complete removal of stones, stone clearance rate reached 97.4%. Of the 33 patients in the control group, 27 patients had stone removal and a clear stone clearance rate of 81.8%, which was significantly different from the experimental group. Conclusion: Ureteroscopic combined with inverted row stone bed treatment of lower calyx stones with good results and safety, the program deserves to continue in the clinical trial, and to promote.